| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
1999-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ed94c4a5af87526a41da10f9ae576d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8485b77d543ee5a32db78fcca398ad7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_797c46629b04f555cfe1826b3c1d375a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd3b5cb8ad200400592b4a0271f37a18 |
| publicationDate |
2002-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002106362-A1 |
| titleOfInvention |
Method for the treatment of chemonucleolysis |
| abstract |
The invention relates to a method of treatment for a mammal in need of chemonucleolysis. The method comprising the administration of an effective proteoglycan cleaving amount of a proteoglycan-degrading enzyme and an effective amount of a growth factor effective in promoting the synthesis of a matrix component. The proteoglycan-degrading enzyme is preferably chondroitinase. The growth factor is preferably osteogenic protein. The proteoglycan-degrading enzyme and the growth factor are preferably administered simultaneously. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007128575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022160845-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2796540-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9061064-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8697139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10286046-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010003691-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8460381-B2 |
| priorityDate |
1998-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |